SCHEMBL6540806

SCHEMBL6540806

C[C@@H]1Cc2cc(O)ccc2[C@@H]2[C@@H]1[C@@H]1CC[C@H](O)[C@@]1(C)C[C@@]2(O)O[N+](=O)[O-]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 14/20 0.39
HDAC3 O15379 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
ESR2 Q92731 8/20 0.39
HSD17B10 Q99714 3/20 0.39
LMNA P02545 3/20 0.39
TSHR P16473 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
NR3C1 P04150 2/20 0.39
PGR P06401 2/20 0.39
CYP3A4 P08684 2/20 0.39
ESRRA P11474 2/20 0.39
CYP2C9 P11712 1/20 0.39
HIF1A Q16665 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC22A1 O15245 1/20 0.39
AKR1B10 O60218 1/20 0.39
SLC22A3 O75751 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8776086 0.83 ESR1 (0.54) ESR1ESR2HSD17B10LMNATSHR
SCHEMBL8775965 0.83 STS (0.34) ESR1ESR2HSD17B10LMNACYP1A2
SCHEMBL16485139 0.72 ESR1 (0.63) ESR1HDAC3HDAC6ESR2HSD17B10
SCHEMBL24103217 0.72 ESR1 (0.63) ESR1HDAC3HDAC6ESR2HSD17B10
SCHEMBL24103220 0.72 ESR1 (0.63) ESR1HDAC3HDAC6ESR2HSD17B10
SCHEMBL24583080 0.72 ESR1 (0.63) ESR1HDAC3HDAC6ESR2HSD17B10
SCHEMBL14569768 0.72 ESR1 (0.63) ESR1HDAC3HDAC6ESR2HSD17B10
SCHEMBL2854638 0.72 ESR1 (0.63) ESR1HDAC3HDAC6ESR2HSD17B10
SCHEMBL8505904 0.72 ESR1 (0.63) ESR1HDAC3HDAC6ESR2HSD17B10
SCHEMBL2854643 0.72 ESR1 (0.63) ESR1HDAC3HDAC6ESR2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0740708-B1 DESIGN OF DRUGS INVOLVING RECEPTOR-LIGAND-DNA INTERACTIONS HENDRY LAWRENCE B (US) 2004-08-04 EP disclosed
US-20020064790-A1 Design of drugs involving receptor-ligand-DNA interactions HENDRY LAWRENCE B (US) 2002-05-30 US disclosed
US-5888741-A Computer-based design and screening of molecules using DNA interactions HENDRY LAWRENCE B (US) 1999-03-30 US disclosed
US-5888738-A Design of drugs involving receptor-ligand-DNA interactions HENDRY LAWRENCE B (US) 1999-03-30 US disclosed
US-5705335-A Design of drugs involving receptor-ligand-DNA interactions HENDRY LAWRENCE B (US) 1998-01-06 US disclosed
EP-0719276-B1 ORALLY ACTIVE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE US HEALTH (US) 1997-11-26 EP disclosed
US-5554603-A 11,17-DINITRATES; USE TO ACHIEVE ESTROGENIC EFFECT IN FEMALE MAMMALS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-09-10 US disclosed
WO-1995007925-A1 ORALLY ACTIVE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1995-03-23 WO disclosed